Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1JAK2 fusion gene: A distinct clinical, pathological and genetic entity with potential treatment target?

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1824-1827

  Prochorec Sobieszek, Monika ^a   Nasiłowska Adamska, Barbara ^b   Borg, Katarzyna ^a   Kopeć, Izabella ^a   Kos Zakrzewska, Kinga ^a   Juszczyński, Przemysław ^a   Warzocha, Krzysztof ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b Department of Hematopoietic Stem Cell Transplantation ^*  (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CYTARABINE; HYDROXYUREA; LACTATE DEHYDROGENASE; RECOMBINANT ALPHA INTERFERON; RETICULIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; BASOPHIL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BLOOD SAMPLING; BONE MARROW BIOPSY; CASE REPORT; CELL PROLIFERATION; CESAREAN SECTION; CHROMOSOME ANALYSIS; CHROMOSOME HIGH RESOLUTION BANDING ANALYSIS; CHROMOSOME TRANSLOCATION 22; CHRONIC LEUKEMIA; CONTROLLED STUDY; DRUG WITHDRAWAL; ECHOGRAPHY; ENZYME BLOOD LEVEL; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIC LEUKEMIA; ERYTHROBLAST; ERYTHROPOIESIS; FEMALE; FIBROSIS; FOLLOW UP; FUSION GENE; GENE MUTATION; GENETICS; GESTATION PERIOD; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LEUKOCYTOSIS; LYMPHOCYTE; MONOCYTE; NEUTROPHIL; NORMOCHROMIC NORMOCYTIC ANEMIA; PATHOLOGY; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROMYELOCYTE; SPLENOMEGALY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; ERYTHROBLASTS; FEMALE; HUMANS; HYDROXYUREA; HYPEREOSINOPHILIC SYNDROME; INFANT, NEWBORN; INTERFERON-ALPHA; ONCOGENE PROTEINS, FUSION; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY COMPLICATIONS, NEOPLASTIC; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864971463     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.661856     Document Type: Letter

References (12)

1. R eiter A, Walz C, Watmore A, et a l. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005;65:2662-2667.
2. Bousquet M, Quelen C, De Mas V, et al. The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005;24:7248-7252.
3. Murati A, Gelsi-Boyer V, Ad élaïde J, et al. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia wiTht(8;9) translocation. Leukemia 2005;19:1692-1696.
4. H eiss S, Erdel M, Gunsilius E, et a l. Myelodysplastic/ myeloproliferative disease wiTherythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): Fi rst description of a case. Hum Pathol 2005;36:1148-1151.
5. Adélaïde J, Pérot C, Gelsi-Boyer V, et a l. A t(8;9) translocation wiThPCM1-JAK2 fusion in a patient wiThT-cell lymphoma. Leukemia 2006;20:536-537.
6. Huang KP, Chase AJ, Cross NC, et al. Evolutional change of karyotype wiTht(8;9)(p22;p24) and HLA-DR immunophenotype in relapsed acute myeloid leukemia. Int J Hematol 2008;88:197-201.
7. D argent JL, Mathieux V, Vidrequin S, et al. Pathology of the bone marrow and spleen in a case of myelodysplastic/myeloproliferative neoplasm associated wiTht(8;9)(p22;p24) involving PCM1 and JAK2 genes. Eur J Haematol 2011;86:87-90.
8. Hoeller S, Walz C, Reiter A, et a l. PCM1-JAK2-fusion: A potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets 2011;15:53-62.
9. Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fi brosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
10. S werdlow SH, Campo E, Harris NL, et al. World HealThOrganization classifi cation of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
11. T akatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol 2008;20:288-294.
12. Buitenhuis M, Verhagen LP, Cools J, et al. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007;67:3759-3766.